KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $119.0 million.

  • CRISPR Therapeutics AG's Total Current Liabilities rose 3245.41% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 3245.41%. This contributed to the annual value of $87.8 million for FY2024, which is 1931.13% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Total Current Liabilities stood at $119.0 million for Q3 2025, which was up 3245.41% from $104.4 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Total Current Liabilities' 5-year high stood at $150.9 million during Q3 2022, with a 5-year trough of $83.1 million in Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $119.0 million (2025), whereas its average is $114.3 million.
  • In the last 5 years, CRISPR Therapeutics AG's Total Current Liabilities surged by 5681.97% in 2022 and then crashed by 2627.16% in 2023.
  • CRISPR Therapeutics AG's Total Current Liabilities (Quarter) stood at $119.9 million in 2021, then increased by 1.02% to $121.1 million in 2022, then fell by 10.17% to $108.8 million in 2023, then decreased by 19.31% to $87.8 million in 2024, then skyrocketed by 35.51% to $119.0 million in 2025.
  • Its last three reported values are $119.0 million in Q3 2025, $104.4 million for Q2 2025, and $119.4 million during Q1 2025.